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OBJECTIVES: This article presents results about risk management indicators per-
formed to HIC (Health Insurance Companies) for CKD (chronic kidney disease) and 
its precursor diseases based on the analysis of large databases achieved through 
the implementation of registry as public policy in Colombia. Also presents the 
economic incentives perceived by them thanks to the good results in risk man-
agement METHODS: CAC (Cuenta de Alto Costo) collects information from HIC in 
Colombia. By law, they report all patients diagnosed with HTA (hypertension),DM 
(diabetes) or CKD in a structure with 81 variables. After the data collection there 
is an audit process and finally, a database of approximately 3.050.000 records is 
obtained which is analyzed and allows the measurement of risk management 
indicators including: early diagnosis of CKD, effectiveness in clinical management, 
progression detention of CKD (less incidence) and calculating the prevalence of 
CKD5. RESULTS: The early diagnosis of CKD is the number of patients with HTA or 
DM studied for CKD corresponding to 38.25 %. The incidence of CKD5 corresponds 
to 11.01 per 100.000 affiliates. The effectiveness in clinical treatment correspond-
ing to the proportion of patient with controlled HTA is 66.54% and finally, the 
calculation of ERC5 prevalence corresponds to 668 ppm. With these results we 
can determine the economic incentives for risk management which is distrib-
uted among the country’s HIC corresponding to USD 44,284,255. CONCLUSIONS: 
Quality record of information as public policy, allows results based evaluation 
which improves attention quality. Of the 52 health insurance companies exist-
ing in Colombia, 25% exceed country risk management goals for all indicators 
and receive a larger sum of money for risk management. Risk management as a 
public policy in Colombia encourages results based competence and contributes 
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OBJECTIVES: We characterize healthcare utilization among congestive heart failure 
(CHF) patients in Israel who survived at least a year after diagnosis. METHODS: 
Adult members of a health maintenance organization in Israel (Maccabi Healthcare 
Services, MHS) who were diagnosed with CHF between January 2006 and December 
2012 were assessed. MHS databases are derived from electronic medical records of 
longitudinal data from a stable population of over 2 million and provide compre-
hensive clinical, demographic and health service data. RESULTS: Of 7691 eligible 
patients followed for 3 years after first diagnosis, 6357 (82.6%) survived ≥ 1year 
following diagnosis (mean age 72.7 years (SD 12.3 years)). During the first 6 months 
following diagnosis, these patients had, on average, 11.3 (SD 7.7), 2.8 (SD 3.0) and 
0.11 (SD 0.5) visits to their primary care physician, cardiologist, and nephrologist, 
respectively, and almost 70% had ≥ 1 hospital admission. Healthcare services use 
decreased after the first 6 months. Men were on average younger than women 
(70.2 vs. 76.0 years), had higher rates of cardiovascular comorbidity and saw a car-
diologist more often (p< 0.001) than women. More women had hypertension and 
chronic kidney disease but saw a nephrologist less often (p< 0.001) than men. In 
the first 6 months following diagnosis, women were hospitalized for longer periods 
than men (10.2 (SD 19.8) vs. 9.0 (SD 18.9) mean cumulative days of hospitalization, 
respectively). Similar trends were observed in primary care physician and hospital 
visits between genders. Patients surviving < 1 year from diagnosis tended to use 
outpatient services less often and inpatient services more often than ≥ 1 year sur-
vivors. CONCLUSIONS: Considerable resources are expended on CHF patients, with 
variations between male and female patients. Observations underscore the consid-
erable healthcare burden of CHF patients, apparent even in this Israeli population, 
diagnosis (2003-2011) and months of drug purchases (2010-2011) were compared 
by month of birth. Trends of diagnosis and treatment were determined for the vari-
ous sub-cohorts, and population sector differences were compared. RESULTS: Of 
total population (400,828 children, 51% male), 40467 (10.1%) were diagnosed with 
ADHD and 33188 (8.3%) were treated (usually methylphenidate). Diagnosis levels 
for younger (Y: Aug-Nov) children (10.9%) were lower than older (O: Dec, Jan-March) 
children (9.2%, RR 1.18 CI 1.16 to 1.21). The rate disparity was higher beginning 
school-year (September-December; RR 1.21 CI 1.17-1.26). Any-purchase dispensing 
RR was 1.19 (CI 1.16 to 1.22), while monthly RR was 1.18 (1.17-1.19). RR for dis-
pensing was stable between age-cohorts (1.17-1.22) without trend. Among children 
purchasing drugs, the seasonal variation in drug purchases (adherence) is similar 
Y:O CONCLUSIONS: ADHD diagnosis and medication are common in the primary 
school population. The increased incidence and prevalence among younger children 
in a cohort questions the appropriateness of both diagnosis and medication, sug-
gesting behavioral treatment may often be more suitable to avoid long term costs 
and deleterious effects, than pharmacological intervention.
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OBJECTIVES: Past experience using third party vendors to administer clinical pro-
grams for patients with chronic, progressive conditions resulted in low opt-in rates. 
A direct approach using the Specialty Pharmacy (SP) may have a better opt-in rate 
and compliance and persistence (C&P) with medication regimens. The objective of 
this interventional program administered by a specialty pharmacy (SP) [Accredo 
Specialty Pharmacy, Memphis, TN] was to evaluate a C&P program for bosentan 
(Actelion Pharmaceuticals Ltd., Allschwil, Switzerland) by comparing Pulmonary 
Arterial Hypertension (PAH) patients in the C&P program to a historical control 
group. METHODS: A pharmacist-based C&P program was administered directly 
by the SP that provided the medication and counseling, and patients were initially 
ranked using Morisky medication adherence scale to assess risk of non-adherence. 
Retrospective analysis was performed to measure program opt-in rate and C&P. 
Claims from a historical group (controls) and from the intervention group (cases) 
that received the SP-based C&P program between 04/29/2013 through 11/30/2013 
were analyzed. Claims for naïve users of bosentan were reviewed at 120 days and 
180 days for both persistence (bosentan claims not spaced > 45 days apart) and 
compliance (number of calendar days supplied with bosentan divided by 120 or 
180 days). Early refills were adjusted when considering days covered. Opt-in rates 
were also measured. RESULTS: Opt-in rate for the enhanced SP-based C&P program 
was robust at 97%. No statistically significant difference was seen between the 
control and case groups for persistence or compliance. Use of the Morisky scale 
to drive the number of pharmacist interventions did not impact outcomes in the 
case group. CONCLUSIONS: SP-based programs can achieve high participation that 
may drive medication compliance, which is essential in progressive diseases like 
PAH. Future programs should be SP-based to replicate the high opt-in rate while 
establishing new interventions to drive compliance and persistence.
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OBJECTIVES: Despite significant advancements in antiretroviral therapy (ART), 
long-term consistent adherence to therapy remains a challenge for many persons 
living with HIV (PLWH). Pharmacists are well-positioned to promote adherence 
to ART beyond mandated dispensing services, but face many barriers, including 
non-reimbursement for adherence promotion activities (APA). Our study exam-
ines the extent to which pharmacists’ barriers (e.g., inadequate staff, no space) 
influence the level of APA in different pharmacy settings. METHODS: We test the 
hypothesis that pharmacists with fewer barriers provide fewer APA to PLWH, using 
generalized linear modelling (GLM). We use factor analysis to generate the APA index 
based on 38 APA (e.g., adherence assessment, customized interventions, monitoring 
activities). RESULTS: We surveyed 225 pharmacists from 41 U.S. states: (22% North 
East; 23% Midwest; 28% West; 27% South). The sample was mostly female (63%) 
Caucasian (66%), and > 30 years (67%). Most pharmacists had a HIV certification 
(68%); 31% worked in specialty-only and 21% in traditional-only pharmacies. Only 
26% of pharmacists reported APA-related reimbursements. Despite most pharma-
cists (95%) reporting > 5 barriers, the barriers index odds ratio (OR) was insignificant 
(OR: 1.007; p< .774). Insurance status [public vs. none (OR: 1.76 (p< .002) & private vs. 
none (OR: 1.90 p< .004)], pharmacy type [specialty vs. traditional (OR: 2.24 p< 0.001)] 
and HIV certification vs. none (OR: 3.65; p< .001) were significant predictors of APA. 
Interestingly, the OR of high volume (> 500 scripts/day) was significant only at 10% 
level (OR: 0.73 p< .07). CONCLUSIONS: The choice of pharmacy largely determines 
PLWH access to adherence promotion services from certified pharmacists. Our find-
ing that pharmacies that invest in HIV certification training are more likely to have 
higher levels of APA has implications for third party payers interested in adherence 
promotion as a cost containment strategy. Despite lack of reimbursement for adher-
ence promotion, many pharmacists are providing these important services to PLWH.
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Excellence (NICE) guidelines. Multivariable logistic regression was performed to 
examine the association between non-indication based PPI use and various patient 
and physician-level characteristics using 2008-2010 NAMCS data. RESULTS: The 
use of PPIs increased from 5.29% patient visits in 2002 to 11.82% in 2010 (p< .0001). 
Prescription of PPI without an appropriate indication by primary care physicians 
(54.26% to 48.84%), medical specialists (35.21% to 35.62%) and surgeons (10.52% 
to 15.53%) did not change significantly between 2005-2010 (p= 0.55). Additionally, 
80.12% of patient visits involved PPI prescriptions without an appropriate indi-
cation. Results of multivariable logistic regression revealed that, patients with 
more than 3 chronic conditions were significantly more likely to be prescribed 
a PPI without an appropriate indication as compared to patient visits without 
a chronic condition (Odds Ratio (OR) = 2.49, 95% Confidence Interval (CI): 1.26-
4.94). CONCLUSIONS: PPI use among the elderly increased significantly over the 
study period, with 8 out of 10 patient visits involving PPI prescriptions without an 
appropriate indication. Additionally, the study found no change in PPI prescribing 
trend across physician specialties. These findings suggest the need to improve 
quality of PPI prescribing in the vulnerable elderly population.
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OBJECTIVES: to estimate the tangible savings generated when there is a joint 
effort between Pharmacist and Physician METHODS: observational descriptive 
study. Population: patient records belonging to an IPS Bogota, diagnosed with 
Osteoporosis in parenteral drug therapy with bisphosphonates (Zoledronic Acid 
5mg Ibandronic Acid 3mg). Observation period: June 2012 to June 2013 (n= 161). The 
Pharmacist identified patients with non-pertinence to parenteral bisphosphonate. 
Non-pertinence was defined when: the patients had osteopenia (no additional risk 
factors), had renal function < 35 ml/min, no previous scaling with oral medications 
and when were men with diagnosis of osteoporosis. Finally, the Physician defined 
the behavior to follow (changing drug therapy). Analysis: were used absolute and 
relative frequencies, measures central tendency and dispersion. Treatment direct 
costs were quantified before and after assessment by the Pharmacist and the 
Physician. The statistical software SPSS 21 license under the CES University was 
used. RESULTS: pharmacist non-pertinence identified in 34% (54/161) of patients, 
of which, the Physician agreed in 70% of cases (38/54). The 39% of patients switched 
to oral bisphosphonates (Calcium Alendronate 70mg, Strontium Ranelate 2mg, 
Risedronate 35mg), 40% Calcium and Vitamin D3 and 21% left without medication. 
Given that patients were pretreated with Zoledronic Acid 5mg (25/38) or Ibandronic 
Acid 3mg (13/38), this conduct involved a decreased 18% a year later, with savings/
year $ 9,164 (considering only the value of the drugs). CONCLUSIONS: the joint 
work between Pharmacist and Physician showed an important saving in rational 
use of medicines.
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OBJECTIVES: To estimate the incidence of polypharmacy and its strength of asso-
ciation with respect to medication regimen among patients (pediatric and adults) 
visiting ED of a tertiary care hospital in Karachi Pakistan. METHODS: Retrospective 
data was collected of all patients, who visited the Emergency Department (ED) of 
Aga Khan University Hospital, Karachi (AKUH) during January, 2012 to December, 
2012. The detailed clinical records on medication prescribing from admission 
through discharge of all patients was reviewed. RESULTS: Total 51,000 patients 
visited ED during January 2012 till December 2012, out of those polypharmacy 
was common in 40% of patients. Male were 56.6%(9,837) while 43.4% (7,553) were 
females. Peadiatric patients were 17.9% (3,145) while 79% (14,279) were adults. The 
most common triage category for patients was P3 with 37.2% (6,483). Most of these 
patients were those who were recommended admission in other wards 59.6% 
(10,146), 26.5% (4,514) discharged patients and 9% (1,536) leave against medical 
advice (LAMA) patients. CONCLUSIONS: The perils and problems associated with 
Poly pharmacy are a subject of interest as polypharmacy was significant finding 
among all ED patients. The results from this study serves as a baseline to iden-
tifying the drug- related problems among EP and could helpful for pharmacists 
and physicians to develop and implement strategy for risk management in ter-
tiary care hospital. keywords: Polypharmacy, Emergency Department, Emergency 
patients.
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OBJECTIVES: Low-cost generic drug programs (LCGPs) offer an affordable way for 
individuals to obtain a wide variety of prescription drugs, but they may lead to 
exposure misclassification in administrative claims datasets. This study sought to 
assess the prevalence and determinants of LCGP use in a privately-insured adult 
population. METHODS: This study relied on data from the Medical Expenditure 
Panel Survey from 2005 – 2011. LCGP use was defined by two stipulations 1) The 
total cost of the drug was paid out of pocket and 2) The cost of the drug exactly 
matched the cost of an LCGP program. Demographics of LCGP users and non-
users were compared. A multivariable logistic model was estimated to identify 
the determinant variables associated with LCGP use. RESULTS: Of the total study 
among the youngest societies in the developed world. Further efforts are required 
to reduce the substantial CHF burden.
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OBJECTIVES: U.S. healthcare spending on high-cost biologics has escalated over the 
past decade. The Biologics Price Competition and Innovation Act allows for biosimi-
lar products in the United States, which will be lower-cost alternatives to reference 
biologics. This study explored payer attitudes to the reimbursement and adoption 
of biosimilars in the United States. METHODS: Some 61 U.S. medical or phar-
macy directors at managed care organizations (MCOs) were surveyed during 2014 
regarding their expectations for biosimilar reimbursement. RESULTS: Respondents 
indicate that MCOs expect biosimilars to offer a significant discount to the refer-
ence brand to secure reimbursement. A mean discount of 23-24% is considered 
adequate for reimbursement, while 33-34% is deemed necessary for preferential 
reimbursement to the reference brand. Rapid formulary inclusion of biosimilars is 
expected, with 79% of respondents indicating formulary inclusion within 12 months 
of launch. Widespread reimbursement of biosimilars in extrapolated indications is, 
however, uncertain, with only 34% of respondents reporting that their MCO would 
unconditionally reimburse a biosimilar under such circumstances. Payers expect 
to employ various strategies to promote biosimilar uptake, from favorable tiering 
to step-therapy requiring biosimilar prescribing prior to the reference brand. The 
most conducive uptake strategies are expected for products with deep discounts. 
In addition, payers will run educational campaigns for physicians. However, ≥ 80% 
of respondents say their biosimilar approach will likely be influenced by thought-
leading physicians and medical associations. Furthermore, widespread “grandfa-
thering” is expected, i.e. continuation of the reference brand in responsive/stable 
patients. CONCLUSIONS: U.S. payers will preferentially promote biosimilars over 
reference brands using various demand- and supply-side measures, so long as bio-
similars meet their discount expectations and have clinical stakeholder buy-in. 
Payers clearly seek to realize the cost savings biosimilars offer; however, tendency 
to seek clinical stakeholder buy-in, coupled with likelihood of extensive “grand-
fathering”, indicates some need for more robust evidence of cost-effectiveness.
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OBJECTIVES: Medical specialists have an essential role in promotion of generic 
medicines. However, misconceptions and negative perceptions about generic medi-
cines among them could be a major barrier to utilization of generic medicines. 
Therefore, the aim of this study was to explore their knowledge, perceptions and 
views about generic medicines. METHODS: A qualitative methodology was adopted 
in this study. A qualitative descriptive (QD) study with phenomenology overtones 
was the research strategy. Face-to-face semi-structured interviews were conducted 
with a purposive sample of medical specialists until saturation of data was achieved. 
The interviews were audio taped and transcribed verbatim. Then, the subsequent 
transcripts were analysed using thematic analysis. The themes were generated 
using both deductive (theoretical) and inductive coding. To ensure reliability of data 
analysis, peer review and independent analysis of the data was done. RESULTS: Five 
major themes were identified: (1) factors affecting specialists’ prescribing practice 
with regards to generic medicines and original brand medicines, (2) specialists’ per-
ceptions of efficacy, safety and quality of generic medicines, (3) specialists’ knowl-
edge and confidence with Malaysian generic regulatory approval system, (4) drug 
information sources used by the specialists and (5) international non-proprietary 
name (INN) prescribing. CONCLUSIONS: The study findings showed that several 
factors influenced prescribing decision with regards to the brands of the medicines 
including familiarity and experience with generic medicines, medical and clinical 
condition of the patient, availability of the medicine brand in the hospital and 
department financial allocations. Moreover, misconceptions about quality, safety, 
efficacy and bioequivalence of generic medicines were prevalent among the partici-
pants. Furthermore, the participants were not familiar with the Malaysian generic 
medicines approval system. Therefore, medical specialists’ concerns need to be 
addressed. Some recommendations and suggestions were made to improve generic 
medicines utilization in the country.
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OBJECTIVES: The study aimed to examine the utilization patterns of Proton Pump 
Inhibitors (PPIs) among the elderly and the trends in PPI prescribing across phy-
sician specialties in US office-based settings. The study also evaluated various 
patient and physician-level factors affecting non-indication based PPI prescrip-
tion in the above population. METHODS: This retrospective cross-sectional study 
used 2002-2010 National Ambulatory Medical Care Survey (NAMCS) and outpa-
tient portion of the National Hospital Ambulatory Medical Care Survey (NHAMCS) 
data to evaluate PPI utilization patterns based on patient visits. PPI prescribing 
trend among different physician specialties was estimated using 2005-2010 
NAMCS data. Evidence-based indications for PPIs included the US Food and Drug 
Administration (FDA) approved indications and the National Institute of Clinical 
